Mastocytosis, Systemic clinical trials

The registry lists 56 studies for Mastocytosis, Systemic across more than 10 countries. 16 are recruiting or about to start. 29 of them are mainly about Mastocytosis, Systemic (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12. Counting its narrower condition Leukemia, Mast-Cell too: 100 studies, 18 open.

Get an email when these change. Save the Mastocytosis, Systemic studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 26
Recruiting: 14
Active, not recruiting: 4
Status unknown: 4
Terminated: 4
Not yet recruiting: 1

Phase

Phase 2: 22
Phase 1: 9
Phase 3: 5
Phase 4: 2

Where

United States: 33
France: 18
Germany: 16
Netherlands: 13
Spain: 13
Italy: 13

Who runs them

Blueprint Medicines Corporation (10) · Novartis Pharmaceuticals (4) · University Hospital, Toulouse (3) · Cogent Biosciences, Inc. (3) · M.D. Anderson Cancer Center (3) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · The First Affiliated Hospital of Soochow University (3) · Jason Robert Gotlib (3)

What is being tested here

Drugs under test in Mastocytosis, Systemic studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Avapritinib	1	0	4
Bezuclastinib	1	0	2
Masitinib	1	2	2
Elenestinib	1	1	2
Flixebrutinib	1	0	1
Midostaurin	0	0	3
Flotetuzumab	0	0	2
Imatinib	0	0	2
Everolimus	0	0	1
Denosumab	0	1	1

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 5 open

Coming up

2phase 3 studies under way

5studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 5

Nov 2026A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies · MacroGenics
Mar 2027Avapritinib With Decitabine in Patients With SM-AHN · H. Lee Moffitt Cancer Center and Research Institute
Jun 2027(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis · Blueprint Medicines Corporation
Jul 2027Angioedema Biomarker Research Study · Foundation For Rare Disease Research
Aug 2027Precision Medicine for Indolent Systemic Mastocytosis (PRISM) · Mayo Clinic

Who these studies take

Of the 14 Mastocytosis, Systemic studies recruiting now, 12 (86%) set no upper age limit and 2 (14%) stop at 75 or younger. 4 (29%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (7%) take healthy volunteers.

Recruiting studies that take each age, of 14
Age	Women	Men
10	3 (21%)	3 (21%)
18	14 (100%)	14 (100%)
30	14 (100%)	14 (100%)
40	14 (100%)	14 (100%)
50	14 (100%)	14 (100%)
65	14 (100%)	14 (100%)
75	14 (100%)	14 (100%)
85	12 (86%)	12 (86%)

Across all 56 studies, recruiting or not: 14% stop at 75 or younger and 2% at 65; 20% take children; 0% are for women only and 0% for men only; 5% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

What changed recently

From the registry's own updates since Oct 14, 2026.

Newly registered1

New Italian Mastocytosis RegistryNov 4, 2026NCT07917156

Studies

Recruiting first, then most recently updated. Showing 50 of 56. Browse all 56 → or search them.